MCID: CRT090
MIFTS: 43

Critical Covid-19

Categories: Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Critical Covid-19

MalaCards integrated aliases for Critical Covid-19:

Name: Critical Covid-19 11 14

Classifications:



External Ids:

Disease Ontology 11 DOID:0081012

Summaries for Critical Covid-19

Disease Ontology: 11 A COVID-19 that is characterized by the criteria for acute respiratory distress syndrome (ARDS), sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy.

MalaCards based summary: Critical Covid-19 is related to non-severe covid-19 and lymphopenia. An important gene associated with Critical Covid-19 is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Crofelemer and Phentolamine have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and heart, and related phenotypes are homeostasis/metabolism and immune system

Related Diseases for Critical Covid-19

Diseases related to Critical Covid-19 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1016)
# Related Disease Score Top Affiliating Genes
1 non-severe covid-19 31.4 TNF TMPRSS2 SERPINA3 IL6 IL10 CXCL8
2 lymphopenia 30.7 IL7 IL6 IL2 IL10 CCR6
3 adult respiratory distress syndrome 30.5 TNF TMPRSS2 SERPINA3 IL6 IL1B IL10
4 nutritional deficiency disease 30.4 SERPINA3 IL6 CRP CCR6
5 thrombocytopenic purpura, autoimmune 30.3 CD8A CD4 CCR6
6 pulmonary fibrosis 30.3 IL1B CXCL8 CCL3 CCL2
7 autoimmune polyendocrine syndrome type 1 30.2 IFNA1 CD4 CCR6
8 autoimmune polyendocrine syndrome 30.2 IFNA1 CD4 CCR6
9 thrombocytopenia due to platelet alloimmunization 30.2 IL10 CD8A CD4 CCR6
10 eosinophilic pneumonia 30.2 IL2 CXCL8 CCL2
11 scleritis 30.2 TNF CRP CCR6 CCL2
12 post-traumatic stress disorder 30.2 IL6 IL1B CRP
13 disseminated intravascular coagulation 30.2 TNF IL6 IL10 CXCL10 CRP CCL2
14 pericardial effusion 30.1 TNF IL6 CRP CD4 ACE2
15 sleep disorder 30.1 TNF IL6 IL1B IL10 CXCL8 CRP
16 covid-19 30.1 TNF TMPRSS2 IL6 IL2 IL1B IL10
17 anxiety 30.1 TNF IL6 IL1B IL10 CXCL8 CRP
18 myasthenia gravis 30.1 TNF IL6 IL2 IL10
19 chronic kidney disease 30.0 TNF IL6 IL1B CRP CCR6
20 pneumonia 30.0 TNF IL6 IL1B IL10 CXCL8 CXCL10
21 hypereosinophilic syndrome 30.0 IL2 IL10 IFNA1 CXCL8
22 toxic shock syndrome 29.9 TNF IL6 IL2 IL1B IL10 CXCL8
23 disease of mental health 29.9 TNF SERPINA3 IL6 IL1B CRP CD4
24 extrinsic allergic alveolitis 29.9 TNF CXCL8 CD8A CD4 CCR6 CCL3
25 cholangitis 29.9 TNF IL6 IL2 IL10 CXCL8 CRP
26 sclerosing cholangitis 29.9 TNF IL6 IL10 CRP CD8A CD4
27 mucormycosis 29.9 TNF IL6 IL10 CSF3 CRP CD8A
28 pre-eclampsia 29.8 TNF IL6 IL1B IL10 CXCL8 CRP
29 liver disease 29.8 TNF SERPINA3 IL6 IFNA1 CCL2
30 cerebrovascular disease 29.8 TNF SERPINA3 IL6 IL1B CRP CCR6
31 herpes zoster 29.8 IL2 IL10 IFNA1 CD8A CD4 CCR6
32 bronchiectasis 29.8 TNF SERPINA3 IL6 IL1B CXCL8 CRP
33 major depressive disorder 29.8 TNF IL6 IL2 IL1B IL10 CRP
34 pulmonary edema 29.8 TNF IL1B IL10 CXCL8 CSF3 CRP
35 substance abuse 29.7 TNF SERPINA3 IL6 IL1B CRP CD4
36 sleep apnea 29.7 TNF IL6 IL1B IL10 CXCL8 CRP
37 purpura 29.7 TNF IL6 IL2 IL1B IL10 CXCL8
38 myopathy 29.6 TNF SERPINA3 IL6 IL1B CRP CD8A
39 vasculitis 29.5 TNF SERPINA3 IL6 IL1B IL10 CXCL8
40 severe acute respiratory syndrome 29.5 TNF TMPRSS2 IL7 IL6 IL2 IL1B
41 aspergillosis 29.4 TNF IL6 IL1B IL10 CXCL8 CXCL10
42 pulmonary tuberculosis 29.4 TNF IL6 IL2 IL1B IL10 CXCL10
43 kidney disease 29.3 TNF IL6 IL2 IL1B IL10 CXCL8
44 cholangitis, primary sclerosing 29.3 TNF IL6 IL1B IL10 CXCL8 CRP
45 myeloma, multiple 29.3 IL7 IL6 IL2 IL1B IFNA1 CSF3
46 neutropenia 29.2 TNF IL6 IL2 IL1B IL10 IFNA1
47 lung disease 29.2 TNF SERPINA3 IL6 IL1B IL10 CXCL8
48 pulmonary disease, chronic obstructive 29.1 TNF SERPINA3 IL6 IL1B CXCL8 CXCL10
49 myocarditis 29.1 TNF IL6 IL2 IL1B IL10 IFNA1
50 exanthem 29.0 TNF IL6 IL2 IL1B IL10 IFNA1

Graphical network of the top 20 diseases related to Critical Covid-19:



Diseases related to Critical Covid-19

Symptoms & Phenotypes for Critical Covid-19

GenomeRNAi Phenotypes related to Critical Covid-19 according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 ACE2 CCL2 CCL3 CCR6 CD4 CD8A
2 no effect GR00402-S-2 10.15 CCL2 CCL3 CCR6 CD4 CRP CSF3

MGI Mouse Phenotypes related to Critical Covid-19:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 ACE2 CCL2 CCL3 CCR6 CD4 CRP
2 immune system MP:0005387 10.13 ACE2 CCL2 CCL3 CCR6 CD4 CD8A
3 neoplasm MP:0002006 10.01 CCL2 IFNB1 IL10 IL1B IL2 IL6
4 cardiovascular system MP:0005385 10 ACE2 CCL2 CCR6 CRP CXCL10 IL10
5 digestive/alimentary MP:0005381 9.92 ACE2 CCL2 CCL3 CD4 IL10 IL2
6 hematopoietic system MP:0005397 9.89 ACE2 CCL2 CCL3 CCR6 CD4 CD8A
7 integument MP:0010771 9.32 ACE2 CCL2 CD4 CD8A CSF3 IL10

Drugs & Therapeutics for Critical Covid-19

Drugs for Critical Covid-19 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Crofelemer Approved Phase 3 33507-63-0, 148465-45-6 36511 44359816
2
Phentolamine Approved Phase 2, Phase 3 50-60-2 5775
3
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
4
Remdesivir Approved, Investigational Phase 3 1809249-37-3 121304016
5
Sargramostim Approved, Investigational Phase 3 123774-72-1
6
Molgramostim Investigational Phase 3 99283-10-0
7
Neurokinin A Phase 3 86933-74-6 55582
8 Adrenergic Antagonists Phase 2, Phase 3
9 Adrenergic alpha-Antagonists Phase 2, Phase 3
10 Neurotransmitter Agents Phase 2, Phase 3
11 Adrenergic Agents Phase 2, Phase 3
12 Antihypertensive Agents Phase 2, Phase 3
13 Gastrointestinal Agents Phase 3
14 Antineoplastic Agents, Hormonal Phase 3
15 Hormones Phase 3
16 Hormone Antagonists Phase 3
17 Antiemetics Phase 3
18 glucocorticoids Phase 3
19 Anti-Inflammatory Agents Phase 3
20 Antibodies, Monoclonal Phase 3
21 Immunoglobulins Phase 3
22 Antibodies Phase 3
23 Immunoglobulin G Phase 3
24
Cannabidiol Approved, Investigational Phase 1, Phase 2 13956-29-1 521372 644019
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
26
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
27
Heparin, bovine Approved, Investigational, Withdrawn Phase 2 9005-49-6 22833565 9812414 772
28
Favipiravir Approved, Investigational Phase 2 259793-96-9 492405
29
Maraviroc Approved, Investigational Phase 2 376348-65-1 3002977
30 Anticonvulsants Phase 1, Phase 2
31 Antibiotics, Antitubercular Phase 2
32 Antiviral Agents Phase 2
33 Anti-Bacterial Agents Phase 2
34 Anti-Retroviral Agents Phase 2
35 Anti-Infective Agents Phase 2
36 Anti-HIV Agents Phase 2
37
Carbamide peroxide Approved 124-43-6
38
Reviparin Approved, Investigational 9041-08-1
39
Prednisolone phosphate Approved, Vet_approved 302-25-0
40
Prednisolone acetate Approved, Vet_approved 52-21-1
41
Acetylsalicylic acid Approved, Vet_approved 50-78-2 2244
42
Prednisolone Approved, Vet_approved 50-24-8 4894 5755
43
Xylometazoline Approved, Investigational 526-36-3 5709
44
Methylprednisolone hemisuccinate Approved 2921-57-5 1875
45
Methylprednisolone Approved, Vet_approved 83-43-2 4159 6741
46
Prednisolone hemisuccinate Experimental 2920-86-7 4897
47 Fibrin fragment D
48
bilirubin 635-65-4 5280352
49 Chrysarobin
50 Calcium heparin

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection Unknown status NCT04326426 Phase 3 Tradipitant;Placebo
2 ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure Completed NCT04311697 Phase 2, Phase 3 Aviptadil by intravenous infusion + standard of care;Normal Saline Infusion + standard of care
3 The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19 - a Post-hoc Analysis of the Blinded, Randomized COVID STEROID 2 Trial Completed NCT05195242 Phase 3 Dexamethasone
4 A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia Active, not recruiting NCT04351152 Phase 3 Standard of Care
5 A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS) Terminated NCT04750278 Phase 2, Phase 3 FP-025 100 mg;FP-025 300 mg;Placebo
6 Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma Terminated NCT04432103 Phase 3
7 Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease Completed NCT04380961 Phase 2 Sirukumab;Placebo
8 A Single-Blind Dose-Ranging Pharmacodynamic Study of Auxora for the Treatment of Patients With Critical COVID-19 Pneumonia Completed NCT04661540 Phase 2 CM4620-IE (Injectable Emulsion);Placebo
9 Cannabidiol Treatment for Severe and Critical COVID-19 Pulmonary Infection Recruiting NCT04731116 Phase 1, Phase 2 Cannabidiol
10 A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) Active, not recruiting NCT04922957 Phase 2 ALLOCETRA-OTS
11 A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Severe and Critical COVID-19 Condition Active, not recruiting NCT05501418 Phase 1, Phase 2
12 Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19" Terminated NCT04475991 Phase 2 Maraviroc + Currently used therapy;Favipiravir + Currently used therapy;Maraviroc+Favipiravir+CT
13 A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia (CARDEA-Plus) Withdrawn NCT05171920 Phase 2 Auxora;Placebo
14 A Randomized, Double-blind, Multicentre 2-arm, Parallel-group, Placebo-controlled Study to Investigate the Efficacy and Safety of Intravenous Imatinib Mesylate in Reducing the Severity of Hypoxemic Respiratory Failure in Patients With Critical COVID-19 Receiving Standard of Care. Withdrawn NCT04953052 Phase 2 Imatinib Mesylate;Placebo
15 Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection Completed NCT04354610
16 Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF Completed NCT04344327
17 Clinical Characteristics and Laboratory Values Affecting Mortality in Critical COVID 19 Patients Followed in the Intensive Care Unit Completed NCT04659876
18 Is Anti-Factor Xa Associated With Mortality, Thromboembolism and Bleeding in Patients With Critical COVID-19 Patients on Low-Molecular-Weight Heparin? Completed NCT05256524 The effect of LMWH
19 A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients Completed NCT04898088
20 Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19 Completed NCT04492501 Tocilizumab;Remdesivir
21 Recovery After Critical Covid-19 Infection Enrolling by invitation NCT04864938
22 Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai Not yet recruiting NCT05422963
23 ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol No longer available NCT04453839 ZYESAMI (aviptadil acetate)

Search NIH Clinical Center for Critical Covid-19

Genetic Tests for Critical Covid-19

Anatomical Context for Critical Covid-19

Organs/tissues related to Critical Covid-19:

MalaCards : Lung, Kidney, Heart, Bone Marrow, T Cells, Liver, Neutrophil

Publications for Critical Covid-19

Articles related to Critical Covid-19:

(show top 50) (show all 1239)
# Title Authors PMID Year
1
Comparison of risk factors and outcome of patients with and without COVID-19-associated pulmonary aspergillosis from Pakistan: A case-control study. 62
36111367 2023
2
Treatment of Severe Hypertriglyceridemia With Insulin Infusions in Severe COVID-19: A Case Series. 62
33882724 2022
3
Remdesivir use in pregnancy during the SARS-CoV-2 pandemic. 62
35168447 2022
4
Corticosteroids: A boon or bane for COVID-19 patients? 62
36029810 2022
5
Efficacy and safety of COVID-19 vaccines. 62
36473651 2022
6
Functional status of recovered critical COVID-19 patients: An assessment of a convalescent cohort. 62
36442914 2022
7
The Importance of Rehabilitation for Functional Recovery and Long-Term Outcomes for Recovery From Critical COVID-19 Illness. 62
36394405 2022
8
Treatment of pregnant and early postpartum women with severe and critical COVID-19: experience at a tertiary center. 62
36461042 2022
9
Sleep and circadian health 6 months after critical COVID-19 disease. 62
36210340 2022
10
Functional status of recovered critical COVID-19 patients: An assessment of a convalescent cohort. 62
35233125 2022
11
Management of Severe and Critical COVID-19 Infection with Immunotherapies. 62
36328635 2022
12
Association between heme oxygenase one and sepsis development in patients with moderate-to-critical COVID-19: a single-center, retrospective observational study. 62
36464717 2022
13
Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh. 62
35238257 2022
14
Performance analyses of prognostic scores in critical COVID-19 patients: think outside the numbers. 62
35792754 2022
15
Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. 62
34839785 2022
16
Risk factors for severe and critical Covid-19 in pregnant women in a single center in Brazil. 62
33535850 2022
17
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. 62
36113538 2022
18
Supportive Care in Patients with Critical Coronavirus Disease 2019. 62
36328636 2022
19
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. 62
36357712 2022
20
Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. 62
33771091 2022
21
Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional study. 62
35918490 2022
22
Challenges and difficulties faced in low- and middle-income countries during COVID-19. 62
36405972 2022
23
Symptomatic versus asymptomatic COVID-19: does it impact placental vasculopathy? 62
35172668 2022
24
Predictors of severe and critical disease in pregnant women with SARS-CoV-2. 62
34470122 2022
25
Autoantibodies against type I IFNs in patients with critical influenza pneumonia. 62
36112363 2022
26
Genome-wide detection of human variants that disrupt intronic branchpoints. 62
36306325 2022
27
Associations between onychomycosis and COVID-19 clinical outcomes: a retrospective cohort study from a US metropolitan center. 62
34773138 2022
28
Potential influence of COVID-19 and dexamethasone on the reproductive system: what we know and can expect. 62
36345876 2022
29
Immune phenotypes that are associated with subsequent COVID-19 severity inferred from post-recovery samples. 62
36433939 2022
30
Survival analysis of patients with COVID-19 admitted at six hospitals in Uganda in 2021: a cohort study. 62
36380388 2022
31
Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study. 62
36443699 2022
32
B-cell malignancies and COVID-19: a narrative review. 62
36336236 2022
33
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. 62
36428621 2022
34
Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients - A retrospective cohort study on 5392 patients from a tertiary centre. 62
36471534 2022
35
COVID-19 related fears and adherence to infection control protocol amongst immunocompromised transplant recipients: A case study. 62
36415242 2022
36
IL-6, IL-10, sFas, granulysin and indicators of intestinal permeability as early biomarkers for a fatal outcome in COVID-19. 62
36209721 2022
37
The oldest unvaccinated Covid-19 survivors in South America. 62
36384671 2022
38
Early intubation and clinical outcomes in patients with severe COVID-19: a systematic review and meta-analysis. 62
36329482 2022
39
Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients. 62
36359306 2022
40
Genetic variants and serum profiles of cytokines in COVID-19 severity. 62
36378234 2022
41
Common mitochondrial haplogroups as modifiers of the onset-age for critical COVID-19. 62
36115538 2022
42
Trends in survival during the pandemic in patients with critical COVID-19 receiving mechanical ventilation with or without ECMO: analysis of the Japanese national registry data. 62
36380377 2022
43
Characteristics of lymphocyte subset alterations in COVID-19 patients with different levels of disease severity. 62
36403042 2022
44
Kinetics of SuPAR hemoadsorption in critical COVID-19 patients on renal replacement therapy. 62
36401202 2022
45
Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. 62
36181987 2022
46
Health-related quality of life among persons with initial mild, moderate, and severe or critical COVID-19 at 1 and 12 months after infection: a prospective cohort study. 62
36324167 2022
47
What is the impact of previous cerebrovascular disease on critical COVID-19 patients' mortality? A prospective cohort study. 62
36037666 2022
48
Neurophysiological Findings in Critical COVID-19 Patients With Peripheral Nervous System Manifestations. 62
36331159 2022
49
Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary. 62
36367599 2022
50
Characteristics of subarachnoid hemorrhage associated with COVID-19 infection: A systematic review and descriptive analysis. 62
36442281 2022

Variations for Critical Covid-19

Expression for Critical Covid-19

Search GEO for disease gene expression data for Critical Covid-19.

Pathways for Critical Covid-19

Pathways related to Critical Covid-19 according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 CCL2 CCL3 CCR6 CD4 CD8A CRP
2
Show member pathways
13.92 TNF IL7 IL6 IL2 IL1B IL10
3
Show member pathways
13.74 CCL2 CCL3 CCR6 CD4 CSF3 CXCL10
4
Show member pathways
13.65 CCL2 CCL3 CD4 CXCL8 IFNA1 IFNB1
5
Show member pathways
13.53 TNF IL7 IL6 IL2 IL1B IL10
6
Show member pathways
13.42 TNF IL7 IL6 IL2 IL1B IL10
7
Show member pathways
13.36 CCL2 CCL3 CD4 CSF3 CXCL10 CXCL8
8
Show member pathways
13.02 IL7 IL6 IL2 IFNB1 IFNA1 CSF3
9
Show member pathways
12.99 CCL3 CXCL10 CXCL8 IFNA1 IFNB1 IL1B
10
Show member pathways
12.94 CCL2 CCL3 CCR6 CD4 CXCL10 CXCL8
11 12.81 IL6 IL1B IL10 CXCL10 CSF3 CCL2
12
Show member pathways
12.78 TNF IL6 IL2 IL1B IL10 IFNB1
13
Show member pathways
12.74 CCL2 CD4 IL10 IL1B IL2 IL6
14 12.72 TNF IL2 IL1B IL10 IFNA1 CXCL10
15
Show member pathways
12.67 TNF IL6 IL1B IFNB1 IFNA1 CXCL8
16
Show member pathways
12.58 CXCL10 CXCL8 IFNB1 IL1B IL6 TNF
17
Show member pathways
12.52 IL6 IL1B IFNB1 IFNA1 CXCL10
18
Show member pathways
12.44 TNF IL6 CXCL8 CXCL10 CSF3 CCL2
19
Show member pathways
12.35 TNF IL6 IL1B CXCL8
20 12.31 TNF IL6 IL1B IL10 CXCL8
21
Show member pathways
12.31 TNF IL2 IL10 IFNB1 CD8A CD4
22
Show member pathways
12.2 CXCL8 CXCL10 CCR6 CCL3 CCL2
23 12.18 TNF IL6 IL1B IL10
24 12.18 CCL2 CXCL10 CXCL8 IL1B IL2 IL6
25 12.16 TNF IL7 IL6 IL2 IL10 CSF3
26
Show member pathways
12.14 IL2 IL1B CD8A CD4 CCL3
27 12.13 TNF IL6 IL1B IL10 CXCL8 CCL2
28 12.11 IL6 IL1B IFNB1 CXCL8 CCL3
29
Show member pathways
12.09 TNF IL6 IL2 IL1B IL10 CD4
30 12.07 IL6 IL10 CXCL8 CCR6 CCL3 CCL2
31 12.05 TNF IL2 IL1B IL10 CXCL8
32 11.94 TNF IL6 IL1B IFNB1 CXCL8 CCL2
33 11.91 TNF IL6 IL2 IL10 CRP
34 11.9 IL6 IL2 IL10 CXCL8 CCL2
35 11.89 IL6 IL2 IL10 CD4
36
Show member pathways
11.89 IL6 IFNB1 CXCL8 CRP CD8A CD4
37 11.85 CD4 IL1B IL2 IL6
38
Show member pathways
11.85 CXCL8 IL1B IL2 IL6 TNF
39 11.85 TNF IL6 IL1B CXCL8 CSF3 CCL3
40 11.84 TNF IL6 IL10 CXCL8 CCL3
41 11.84 CD4 CD8A IFNB1 IL10 IL1B IL2
42
Show member pathways
11.83 TNF IL1B IFNB1
43 11.81 IL6 IL2 CXCL8
44 11.81 TNF IL6 IL1B IL10
45 11.81 CCL3 CCR6 CD4 CD8A IL10 IL1B
46
Show member pathways
11.78 TNF IL6 IL2 IL10
47
Show member pathways
11.77 SERPINA3 IL6 CCL2
48
Show member pathways
11.75 TNF IL2 CXCL8
49 11.71 TNF IL6 CXCL8 CCL2
50 11.71 TNF IL10 IFNB1 CXCL8 CCL3 CCL2

GO Terms for Critical Covid-19

Cellular components related to Critical Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.16 ACE2 CCL2 CCL3 CRP CSF3 CXCL10
2 extracellular region GO:0005576 9.88 ACE2 CCL2 CCL3 CD8A CRP CSF3

Biological processes related to Critical Covid-19 according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.47 CCL2 CCL3 CCR6 CD4 CSF3 CXCL10
2 positive regulation of gene expression GO:0010628 10.42 CCL3 CRP CXCL8 IL1B IL6 IL7
3 cell-cell signaling GO:0007267 10.35 IL7 IL2 IL1B CXCL10 CCL3
4 chemotaxis GO:0006935 10.29 CCL2 CCL3 CCR6 CXCL10 CXCL8
5 defense response to Gram-positive bacterium GO:0050830 10.28 TNF IL6 IL1B CRP
6 inflammatory response GO:0006954 10.28 CCL2 CCL3 CRP CXCL10 CXCL8 IL1B
7 positive regulation of DNA-binding transcription factor activity GO:0051091 10.27 CSF3 IL10 IL1B IL6 TNF
8 positive regulation of inflammatory response GO:0050729 10.25 TNF IL2 IL1B CCL3
9 cellular response to virus GO:0098586 10.22 IL6 IFNB1 IFNA1 CXCL10
10 cellular response to organic cyclic compound GO:0071407 10.19 TNF IL1B CCL3 CCL2
11 protein kinase B signaling GO:0043491 10.18 TNF IL1B CCL3 CCL2
12 B cell proliferation GO:0042100 10.16 IL7 IL10 IFNB1 IFNA1
13 acute-phase response GO:0006953 10.15 SERPINA3 IL6 CRP
14 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.14 TNF IL7 IL1B
15 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.14 TNF IL6 IL10
16 calcium-mediated signaling GO:0019722 10.13 CCL3 CCR6 CD4 CXCL8 TNF
17 liver regeneration GO:0097421 10.12 IL10 IL6 TNF
18 positive regulation of immunoglobulin production GO:0002639 10.11 IL6 IL2 IL10
19 negative regulation of neurogenesis GO:0050768 10.1 IL1B IL6 TNF
20 neutrophil chemotaxis GO:0030593 10.1 IL1B CXCL8 CXCL10 CCL3 CCL2
21 cytokine-mediated signaling pathway GO:0019221 10.1 IL7 IL6 IL1B IFNB1 IFNA1 CSF3
22 positive regulation of chemokine production GO:0032722 10.09 IL1B IL6 IL7 TNF
23 positive regulation of glial cell proliferation GO:0060252 10.08 TNF IL6 IL1B
24 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.08 TNF IL1B IL10
25 lipopolysaccharide-mediated signaling pathway GO:0031663 10.08 TNF IL1B CCL3 CCL2
26 chemokine-mediated signaling pathway GO:0070098 10.07 CCL2 CCL3 CCR6 CXCL10 CXCL8
27 cellular response to lipopolysaccharide GO:0071222 10.03 CCL2 CSF3 CXCL10 CXCL8 IL10 IL1B
28 positive regulation of neuroinflammatory response GO:0150078 10 TNF IL6 IL1B
29 negative regulation of lipid storage GO:0010888 9.99 TNF IL6 CRP
30 negative regulation of cytokine production involved in immune response GO:0002719 9.98 TNF IL10
31 positive regulation of fever generation GO:0031622 9.98 TNF IL1B
32 cellular response to interleukin-17 GO:0097398 9.97 IL1B CXCL10
33 sequestering of triglyceride GO:0030730 9.96 IL1B TNF
34 positive regulation of plasma cell differentiation GO:1900100 9.94 IL2 IL10
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.94 TNF IL1B
36 defense response GO:0006952 9.93 TNF IFNB1 IFNA1 CXCL8 CXCL10
37 vascular endothelial growth factor production GO:0010573 9.93 TNF IL6 IL1B
38 chronic inflammatory response to antigenic stimulus GO:0002439 9.92 TNF IL10
39 humoral immune response GO:0006959 9.8 CCL2 CCR6 IFNA1 IFNB1 IL6 IL7
40 immune response GO:0006955 9.62 TNF IL7 IL6 IL2 IL1B IL10

Molecular functions related to Critical Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.85 IL7 IL6 IL2 IL10 CSF3
2 cytokine activity GO:0005125 9.66 CCL2 CCL3 CSF3 CXCL10 CXCL8 IFNA1
3 cytokine receptor binding GO:0005126 9.56 IL7 IFNB1 IFNA1
4 chemokine activity GO:0008009 9.56 CXCL8 CXCL10 CCL3 CCL2

Sources for Critical Covid-19

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....